Inducible re-expression of HEXIM1 causes physiological cardiac hypertrophy in the adult mouse

Cardiovascular Research

Volumn 99, Issue 1, 2013, Pages 74-82

  Montano, Monica M ^a   Desjardins, Candida L ^b   Doughman, Yong Qui ^a   Hsieh, Yee Hsee ^a   Hu, Yanduan ^a   Bensinger, Heather M ^a   Wang, Connie ^a   Stelzer, Julian E ^a   Dick, Thomas E ^a   Hoit, Brian D ^a   Chandler, Margaret P ^a   Yu, Xin ^b   Watanabe, Michiko ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Angiogenesis; HEXIM1; Hypertrophy

Indexed keywords

HEXAMETHYLENE BIS ACETAMIDE INDUCIBLE PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR GATA 4; TRANSCRIPTION FACTOR HEXIM1; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; GENE CONTROL; HEART EJECTION FRACTION; HEART FUNCTION; HEART VENTRICLE HYPERTROPHY; MOUSE; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METABOLISM; VASCULARIZATION;

ANGIOGENESIS; HEXIM1; HYPERTROPHY;

ANIMALS; CARDIOMEGALY; CELLS, CULTURED; ECHOCARDIOGRAPHY; GATA4 TRANSCRIPTION FACTOR; GENE EXPRESSION REGULATION; GENOTYPE; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MAGNETIC RESONANCE IMAGING; MICE; MICE, TRANSGENIC; MYOCYTES, CARDIAC; NEOVASCULARIZATION, PHYSIOLOGIC; PHENOTYPE; PHYSICAL ENDURANCE; PPAR ALPHA; PROTO-ONCOGENE PROTEINS C-MYC; STROKE VOLUME; TRANSCRIPTION FACTORS; TRANSFECTION;

EID: 84879356036     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvt086     Document Type: Article

References (47)

1. Weeks KL, McMullen Jr. The athlete's heart vs. the failing heart: can signaling explain the two distinct outcomes? Physiology (Bethesda) 2011;26:97-105
2. Dey A, Chao SH, Lane DP. HEXIM1 and the control of transcription elongation: from cancer and inflammation to AIDS and cardiac hypertrophy. Cell Cycle 2007;6: 1856-1863 (Pubitemid 47327903)
3. Montano MM, Doughman YQ, Deng H, Chaplin L, Yang J,WangNet al. Mutation of the HEXIM1 gene results in defects during heart and vascular development partly through downregulation of vascular endothelial growth factor. Circ Res 2008;102:415-422 (Pubitemid 351651100)
4. Yu Z, Redfern CS, Fishman GI. Conditional transgene expression in the heart. Circ Res 1996;79:691-697 (Pubitemid 26317816)
5. Ogba N, Chaplin L, Doughman YQ, Fujinaga K, Montano MM. HEXIM1 regulates E2/ ERa-mediated expression of Cyclin D1 in mammary cells via modulation of P-TEFb. Cancer Res 2008;68:7015-7024
6. English BA, Appalsamy M, Diedrich A, RuggieroAM, Lund D, Wright J et al. Tachycardia, reduced vagal capacity, and age-dependent ventricular dysfunction arising from diminished expression of the presynaptic choline transporter. Am J Physiol Heart Circ Physiol 2010;299:H799-H810
7. Zhong J, Yu X. Strain and torsion quantification in mouse hearts under dobutamine stimulation using 2D multiphase MR DENSE. Magn Reson Med 2010;64:1315-1322
8. Hoit BD.Newapproaches to phenotypic analysis in adult mice. J Mol Cell Cardiol 2001;33: 27-35 (Pubitemid 32127781)
9. Cesarovic N, Jirkof P, Rettich A, Arras M. Implantation of radiotelemetry transmitters yielding data on ECG, heart rate, core body temperature and activity in free-moving laboratory mice. J Vis Exp 2011;57:1-6
10. Haldar SM, Lu Y, Jeyaraj D, Kawanami D, Cui Y, Eapen SJ et al. Klf15 deficiency is a molecular link between heart failure and aortic aneurysm formation. Sci Transl Med 2010;2:26ra26.
11. Kimes BW, Brandt BL. Properties of a clonal muscle cell line from rat heart. Exp Cell Res 1976;98:367-381
12. Montano MM, Katzenellenbogen BS. The quinone reductase gene: a unique estrogen receptor-regulated gene that is activated by antiestrogens. Proc Natl Acad Sci USA 1997;94:2581-2586 (Pubitemid 27136918)
13. Wittmann BM, Wang N, Montano MM. Identification of a novel inhibitor of cell growth that is down-regulated by estrogens and decreased in breast tumors. Cancer Res 2003;63:5151-5158 (Pubitemid 37022657)
14. Breitenbach I, Harringer W, Tsui S, Amorim MJ, Herregods MC, Bogaert J et al. Magnetic resonance imaging versus echocardiography to ascertain the regression of left ventricular hypertrophy after bioprosthetic aortic valve replacement: results of the REST study. J Thorac Cardiovasc Surg 2011;144:640-645
15. Jeron A, Mitchell GF, Zhou J, MurataM, London B, Buckett P et al. Inducible polymorphic ventricular tachyarrhythmias in a transgenic mouse model with a long Q-T phenotype. Am J Physiol Heart Circ Physiol 2000;278:H1891-H1898 (Pubitemid 30439201)
16. Korf-Klingebiel M, Kempf T, Schlu?ter KD, Willenbockel C, Brod T, Heineke J et al. Conditional transgenic expression of fibroblast growth factor 9 in the adult mouse heart reduces heart failure mortality after myocardial infarction. Circulation 2011;123: 504-514
17. Mazure NM, Brahimi-Horn MC, Berta MA, Benizri E, Bilton RL, Dayan F et al. HIF-1: master and commander of the hypoxic world. A pharmacological approach to its regulation by siRNAs. Biochem Pharmacol 2004;68:971-980 (Pubitemid 39094259)
18. Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DRet al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 2001;107:43-54 (Pubitemid 32972036)
19. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygendependent proteolysis. Nature 1999;399:271-275 (Pubitemid 29246458)
20. Oka T, Xu J, Molkentin JD. Re-employment of developmental transcription factors in adult heart disease. Semin Cell Dev Biol 2007;18:117-131 (Pubitemid 46330840)
21. Liu HB, Yang BF, Dong DL. Calcineurin and electrical remodeling in pathologic cardiac hypertrophy. Trends Cardiovasc Med 2010;20:148-153
22. Taigen T, De Windt LJ, Lim HW, Molkentin JD. Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy. Proc Natl Acad Sci USA 2000;97: 1196-1201 (Pubitemid 30080835)
23. Tuunanen H, Knuuti J. Metabolic remodelling in human heart failure. Cardiovasc Res 2011; 90:251-257
24. Ahuja P, Zhao P, Angelis E, Ruan H, Korge P, Olson A et al. Myc controls transcriptional regulation of cardiac metabolism and mitochondrial biogenesis in response to pathological stress in mice. J Clin Invest 2010;120:1494-1505
25. Lee HG, Chen Q, JA W, Richardson SL, Liner A, Siedlak SL et al. Cell cycle re-entry and mitochondrial defects in myc-mediated hypertrophic cardiomyopathy and heart failure. PLoS One 2009;4:e7172
26. Wagner N, Jehl-Pietri C, Lopez P, Murdaca J, Giordano C, Schwartz C et al. Peroxisome proliferator-activated receptor beta stimulation induces rapid cardiac growth and angiogenesis via direct activation of calcineurin. Cardiovasc Res 2009;83:61-71
27. Aoyagi T, Matsui T. Phosphoinositide-3 kinase signaling in cardiac hypertrophy and heart failure. Curr Pharm Des 2011;17:1818-1824
28. Semenza GL, Shimoda LA, Prabhakar NR. Regulation of gene expression by HIF-1. Novartis Found Symp 2006;272:2-8
29. Heineke J, Auger-Messier M, Xu J, Oka T, Sargent MA, York A et al. Cardiomyocyte GATA4 functions as a stress-responsive regulator of angiogenesis in the murine heart. J Clin Invest 2007;117:3198-3210 (Pubitemid 350096978)
30. Reuben RC, Wife RL, Breslow R, Rifkind RA, Marks PA. A new group of potent inducers of differentiation in murine erythroleukemia cells. Proc Natl Acad Sci USA 1976;73: 862-866
31. Huang F,Wagner M, Siddiqui MA. Ablation of the CLP-1 gene leads to down-regulation of the HAND1 gene and abnormality of the left ventricle of the heart and fetal death. Mech Dev 2004;121:559-572 (Pubitemid 38681211)
32. Sano M, Abdellatif M, Oh H, Xie M, Bagella L, Giordano A et al. Activation and function of cyclin T-Cdk9 (positive transcription elongation factor-b) in cardiac muscle-cell hypertrophy. Nat Med 2002;8:1310-1317 (Pubitemid 35373565)
33. Sano M, Wang SC, Shirai M, Scaglia F, Xie M, Sakai S et al. Activation of cardiac Cdk9 represses PGC-1 and confers a predisposition to heart failure. EMBO J 2004;23: 3559-3569 (Pubitemid 39265545)
34. Espinoza-Derout J, Wagner M, Salciccioli L, Lazar JM, Bhaduri S, Mascareno E et al. Positive transcription elongation factor b activity in compensatory myocardial hypertrophy is regulated by cardiac lineage protein-1. Circ Res 2009;104:1347-1354
35. Yoshikawa N, Shimizu N, Maruyama T, Sano M, Matsuhashi T, Fukuda K et al. Cardiomyocyte-specific overexpression of HEXIM1 prevents right ventricular hypertrophy in hypoxia-induced pulmonary hypertension in mice. PLoS One 2012;7:e52522
36. Kido M, Du L, Sullivan CC, Li X, Deutsch R, Jamieson SW et al. Hypoxia-inducible factor 1-alpha reduces infarction and attenuates progression of cardiac dysfunction after myocardial infarction in the mouse. J Am Coll Cardiol 2005;46:2116-2124 (Pubitemid 41713601)
37. Hyva?rinen J, Hassinen IE, Sormunen R, Ma?ki JM, Kivirikko KI, Koivunen P et al. Hearts of hypoxia-inducible factor prolyl 4-hydroxylase-2 hypomorphic mice show protection against acute ischemia-reperfusion injury. J Biol Chem 2010;285:13646-13657
38. Eckle T, Ko? hler D, Lehmann R, El Kasmi K, Eltzschig HK. Hypoxia-inducible factor-1 is central to cardioprotection: a new paradigm for ischemic preconditioning. Circulation 2008;118:166-175
39. Krishnan J, Suter M, Windak R, Krebs T, Felley A, Montessuit C et al. Activation of a HIF1alpha-PPARgamma axis underlies the integration of glycolytic and lipid anabolic pathways in pathologic cardiac hypertrophy. Cell Metab 2009;9:512-524
40. Abel ED, Kaulbach HC, Tian R, Hopkins JC, Duffy J, Doetschman T et al. Cardiac hypertrophy with preserved contractile function after selective deletion of GLUT4 from the heart. J Clin Invest 1999;104:1703-1714 (Pubitemid 30053187)
41. Kaplan ML, Cheslow Y, Vikstrom K, Malhotra A, Geenen DL, Nakouzi A et al. Cardiac adaptations to chronic exercise in mice. Am J Physiol 1994;267:H1167-H1173
42. Diep Q, Amiri F, Touyz R, Cohn J, Endelman D, Schiffrin E. PPARa activator effects on Ang II-induced vascular oxidative stress and inflammation. Hypertension 2002;40: 866-871 (Pubitemid 35434908)
43. Abel ED, Doenst T. Mitochondrial adaptations to physiological vs. pathological cardiac hypertrophy. Cardiovasc Res 2011;90:234-242
44. Raven PB, Fadel PJ, Ogoh S. Arterial baroreflex resetting during exercise: a current perspective. Exp Physiol 2006;91:37-49
45. RowlandT. Is the 'athlete's heart' arrhythmogenic? Implications for sudden cardiac death. Sports Med 2011;41:401-411
46. Zhang RL, Christensen LP, Tomanek RJ. Chronic heart rate reduction facilitates cardiomyocyte survival after myocardial infarction. Anat Rec (Hoboken) 2010;293: 839-848
47. Canet E, Lerebours G, Vilaine JP. Innovation in coronary artery disease and heart failure: clinical benefits of pure heart rate reduction with ivabradine. AnnNY Acad Sci 2011;1222: 90-99.